Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

A long‑standing reason karela finds its way into morning routines is its potential to support glucose control. Bitter gourd ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other ...

Karela, also known as bitter gourd, can be beneficial in managing diabetes. Here is how it can help, as well as the possible side affects you need to be wary of.

Viking Therapeutics grew its share prices by 11.89 percent on Wednesday to finish at $34.34 apiece as investors took heart ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

When endocrinologist Dan Bessesen, MD, looked online and saw how easy it would be for him to purchase a weight loss drug from ...

What started out as a medication for diabetes and weight loss is offering something quite unexpected for many women. Experts ...